A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

Melasma Clinical Trial

Official title:

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02110134
• Other study ID #: CYN13-REV-TOP-MEL-AK
• Status: Completed
• Phase: N/A
• Start date: December 2013
• Est. completion date: May 2014

Study information

• Verified date: November 2020
• Source: Cynosure, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with Fitzpatrick Skin Type III-VI

• Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.

• Subjects who are over the age of 18 years of age

• The subject is willing and able to comply with study instructions and return to the clinic for required visits.

• The subject's melasma has persisted for greater than 6 months

Exclusion Criteria:

• The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.

• The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.

• The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.

• The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).

• The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.

• The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.

• The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.

• The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.

• The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).

• The subject has Diabetes Type 1 or 2.

• The subject has a sensitivity to hydroquinone or Retin-A.

• The subject has evidence of a compromised immune system or hepatitis.

• Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.

• Has a history of keloids or hypertrophic scarring

• Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study

Related Conditions & MeSH terms

• Melanosis
• Melasma

Intervention

Device:
• Revlite Laser System with hydroquinone skin care regimen
Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma

Other:
• Hydroquinone skin care regimen
Hydroquinone skin care regimen for the Treatment of Melasma

Locations

Country	Name	City	State
United States	NY Laser and Skin Care	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Cynosure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rates of Adverse Events Among Patients	Adverse events were collected and reported to test the safety and efficacy of the device.	From study baseline to completion, approximately 1 year. However, adverse events not resolved by then will be followed up with until they are resolved.
Secondary	Satisfaction Questionnaire	Physician and subject satisfaction will be ranked on a scale from 1 to 5, where 1 is extremely dissatisfied and 6 is extremely satisfied.	1 month post last treatment
Secondary	Photographic Evaluation using the Global Aesthetic Improvement Scale	Photos will be a taken at baseline and post treatment and then improvement assessed using the Global Aesthetic Improvement Scale. This scale ranges from 0 to 3, where 0 is 0-25% clearance from baseline photograph, 1 is 25-50% clearance from baseline photograph, 2 is 50-75% clearance from baseline photograph, and 3 is 75-100% clearance from baseline photograph.	1 month post last treatment